# University of Pennsylvania HIV Clinical Trials Unit

> **NIH NIH UM1** · UNIVERSITY OF PENNSYLVANIA · 2021 · $3,690,931

## Abstract

ABSTRACT
The University of Pennsylvania HIV Clinical Trials Unit (Penn HIV CTU) will build on its current infrastructure
and further its commitment to provide scientific leadership to advance the science of HIV treatment and
prevention within three HIV Clinical Research Networks, the Adult AIDS Clinical Trials Group (ACTG), the HIV
Vaccine Trials Group (HVTN), and the HIV Prevention Trials Group (HPTN). The Penn HIV CTU features an
integrated, efficient clinical trials organization with two clinical research sites (CRS), the Penn Therapeutics
CRS, located on the Penn School of Medicine (PSOM) campus, that conducts ACTG trials; and the Penn
Prevention CRS, separately located on the Penn campus, that conducts HVTN and HPTN supported trials.
Penn investigators will continue to contribute to the scientific agendas of these Networks through participation
on network committees and through submission of protocols and membership on protocol teams. In addition,
the Penn HIV CTU will advance the research agendas of these Networks through the cost efficient
implementation of clinical trials to improve the lives of people living with HIV infection and to prevent it among
those at risk. The leadership of the Penn HIV CTU will mentor the next generation of clinical investigators by
involving junior investigators at our site and elsewhere in activities at that promote their career development at
both the Network and site level. Penn investigators will engage the local community affected by HIV when
formulating priorities, we will inform the community about opportunities to participate in research, and educate
the community about medical advances and opportunities to access them. Penn investigators have
contributed to important advances in HIV therapeutics through the evaluation of strategies designed to control
HIV replication in the absence of antiretrovirals and purge the latent reservoir, testing of novel agents to inhibit
HIV replication, and by improving treatments and prevention of co-morbid conditions associated with HIV
infection. Penn investigators have also contributed to advances in HIV prevention through the testing of HIV
vaccines, long-acting antiretrovirals and monoclonal antibodies for pre-exposure prophylaxis, and through
behavioral interventions designed to modify risk behaviors. It is our goal to make these advances available to
all populations living with or at-risk for HIV infection, including men who have sex with men, cisgender women,
transgender and gender non-conforming individuals, and persons who inject drugs. Given the resources,
vision, and commitment of Penn investigators, the Penn HIV CTU is well positioned to support the initiative for
Ending the HIV Epidemic in Philadelphia, a priority city, through achievements in HIV prevention, diagnosis,
treatment.

## Key facts

- **NIH application ID:** 10057768
- **Project number:** 2UM1AI069534-15
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Ian Frank
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $3,690,931
- **Award type:** 2
- **Project period:** 2007-02-01 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10057768

## Citation

> US National Institutes of Health, RePORTER application 10057768, University of Pennsylvania HIV Clinical Trials Unit (2UM1AI069534-15). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10057768. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*